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A ntiglomerular basement membrane (anti-GBM)disease presents with rapidly progressive
glomerulonephritis, often associated with alveolar
hemorrhage and characterized histologically by cres-
centic glomerulonephritis. Typically, there is linear
deposition of Ig along the glomerular basement mem-
brane (GBM), which, in the majority of cases, is due to
IgG autoantibodies directed against the noncollagenous
domain of the a3 chain of type IV collagen (a3[IV]
NC1).1
Early disease recognition relies on detecting circu-
lating IgG anti-GBM antibodies in serum samples.
However, conventional assays do not detect IgA anti-
bodies or those directed against other target antigens,
including a5(IV) found in some Alport disease patients
following renal transplantation.2 The presence and
speciﬁcity of the antibody can be conﬁrmed by
Western blotting, usually at a reference center,
although this is not routinely performed.
We describe a case of anti-GBM disease mediated by
IgA anti-GBM antibodies not detected by standard
serological tests, and suggest a method of detection and
monitoring that can be used in the right clinical
context.
CASE PRESENTATION
A 37-year-old Turkish man presented with a 2-month
history of breathlessness, chest pain, and weight loss.
He worked as a hairdresser and had no past medical
history. Investigation revealed bilateral pleuralInternational Reports (2019) 4, 163–167effusions and a pericardial effusion. The pleural effu-
sion was tapped at the referring hospital, revealing an
exudate. Pending the AFB culture of his pleural aspi-
rate, he was started on empirical treatment for pre-
sumed tuberculous pleuro-pericarditis. Three weeks
later, he was admitted to hospital with new-onset acute
kidney injury requiring hemodialysis, and 1 week later
was transferred to our renal unit for ongoing manage-
ment. His serum creatinine was 1108 mmol/l, Hb 72 g/l,
phosphate 3.73 mmol/l, and serum bicarbonate 16
mmol/l. His pleural aspirate was negative for AFB. He
was still passing urine with nephrotic-range protein-
uria (urine protein-to-creatinine ratio: 1110 mg/mmol,
normal range <30) and microscopic hematuria. Immu-
nological test results were negative for anti-GBM an-
tibodies by enzyme-linked immunosorbent assay (EliA,
Phadia using recombinant a3 chain of collagen IV as
target). Antinuclear antibodies (ANAs) and anti-
neutrophil cytoplasm antibodies (ANCAs) were nega-
tive; complement C3 and C4 levels were normal; IgG,
IgM, and IgA were normal; and no paraprotein was
found in serum or urine. Ultrasound examination
revealed 11-cm kidneys with normal corticomedullary
differentiation. Computed tomography ruled out sig-
niﬁcant alveolar hemorrhage.
A kidney biopsy was performed. Histopathological
examination revealed acute diffuse and global cres-
centic glomerulonephritis on the background of mod-
erate chronic damage (Figure 1a). A total of 19
glomeruli were present, 3 of which were obsolete. All
patent tufts were severely shrunken and some oblit-
erated by large cellular crescents. The vessels showed163
Figure 1. Patient renal biopsy tissue stained with (a) hematoxylin
and eosin, showing a large circumferential cellular crescent asso-
ciated with compression of the glomerular tuft, and (b) by immu-
nohistochemistry for IgA, showing linear IgA deposition along the
glomerular basement membrane, Bowman’s capsule, and mesangial
matrix.
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poles. There was no deposition of IgG in glomeruli, but
there was linear deposition of complement C3 and IgA
along the GBM as well as the Bowman’s capsule, the
glomerular mesangium, and the tubular basement
membranes (Figure 1b).
The patient received 3 pulses of methylprednisolone
and daily plasma exchange. In view of his prolonged
dialysis dependence and the extensive chronic damage
on the biopsy sample, he was not treated with cyclo-
phosphamide, but started mycophenolate mofetil in an
attempt to accelerate autoantibody removal to facilitate
transplantation. As there are no standard means for
following the levels of circulating IgA anti-GBM anti-
bodies, we modiﬁed an indirect immunoﬂuorescence
method, using patient serum to stain primate kidney
sections, which conﬁrmed prominent linear IgA bind-
ing to the glomerular and tubular basement membranes
and to the Bowman’s capsule, accompanied by weaker
IgA binding to mesangial areas with the patient’s acute
serum (Figure 2). It was reassuring that there was noFigure 2. Indirect immunoﬂuorescence staining of primate kidney section
4 C with (left) control patient serum with IgG antibodies against the nonco
acute, and (right) patient convalescent serum. Patient’s and control se
647labeled secondary antibodies (diluted 1:1000) to human IgA (diluted
164such staining with convalescent serum obtained 9
months after treatment initiation (Figure 2), allowing
him to be placed on the transplant waiting list. The
patient received a cadaveric renal transplant 12 months
later. At the 9-month follow-up, his serum creatinine
was 104 mmol/l, with no evidence of urinary abnor-
malities suggesting disease recurrence.DISCUSSION
Commonly, IgG anti-GBM antibodies bind the a3
subunit of the noncollagenous (NC1) domain of type IV
collagen a3(IV)NC1, distributed along the glomerular,
alveolar, and cochlear basement membranes as well as
the distal tubular basement membranes, resulting in
linear GBM staining (Figure 2) on renal immunohisto-
chemistry. However, the IgA staining pattern that we
noted in this case appeared different, with additional
prominent Bowman’s capsule and mesangial and
diffuse tubular basement membrane staining, suggest-
ing a potentially different target epitope.
We used western blot analysis of the acute serum to
characterize the IgA anti-GBM epitope. Using type IV
collagen derived from collagenase-digested human
GBM, no binding was found. However, using intact
type IV collagen derived from human ﬁbroblasts, we
found IgA binding to proteins of molecular weights
100 and 150 kDa (Figure 3a), conﬁrming that the IgA
antibodies reacted with a collagenous portion of the
molecule. As type IV collagen derived from human ﬁ-
broblasts contains only a1(IV) and a2(IV) chains but no
a3(IV) to a6(IV) chains, our data imply that the IgA
anti-GBM antibodies bound the collagenous domains of
a1(IV) or a2(IV) collagen chains (Figure 3b).
To specify whether the IgA antibody is targeted
against the a1(IV) or a2(IV) collagen chains, we per-
formed immunoﬂuorescence on human skin ﬁbroblastss (Euroimmun, product number FB 1250-1010) incubated overnight at
llagenous domain of the a3 chain of type IV collagen, (center) patient
ra (diluted 1:10) antibody binding was visualized with Alexa Fluor
1:250; center, right) or IgG (diluted 1:500, left).
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Figure 3. Western blot analysis of the circulating IgA antibody
reactivity with type IV collagen. (a) Type IV collagen antigens
derived from human ﬁbroblasts and epithelial cells (Collagen Type IV
from human cell culture, Bornstein and Traub Type IV, Sigma) were
separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) (6% Trisglycine gels) under nonre-
ducing conditions and transferred to Immobilon P membranes for
immunoblotting with patient acute serum (diluted 1:10), which was
subsequently stained with a biotinylated antibody to human IgA
(diluted 1:250) and visualized with horseradish
peroxidasestreptavidin (diluted 1:1000). (b) Schematic represen-
tation of type IV collagen protomers (triple helical molecules). GBM,
glomerular basement membrane; NC, noncollagenous domain.
Figure 4. Immunoﬂuorescence of human skin ﬁbroblasts. Fibroblasts w
(Thermoﬁsher) (5  104 cells/slide), fixed, blocked with 5% goat serum, a
(catalog number MAB6308) at 10 mg/ml for 3 hours at room temperature and
serum and (e) serum from a healthy control (all at dilution 1:10) incuba
secondary antibodies (diluted 1:1000) to human IgA (diluted 1:250). (c) Me
bodies in the patient’s acute serum and a1 chains of type IV collagen.
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Kidney International Reports (2019) 4, 163–167from healthy controls. In skin ﬁbroblasts, collagen IV is
a heterotrimeric molecule containing two a1 and one
a2 chains. Cells were stained with acute patient serum
visualized by Alexa Fluor 647labeled antibody to
human IgA and a mouse monoclonal antibody against
the a1(IV). We found extensive expression of IgA on
ﬁbroblasts with the patient’s acute serum, which
colocalized with the monoclonal antibody staining to
the a1 chain of type IV collagen. There was no such
IgA binding found with the patient’s convalescent
serum or serum from a healthy control (Figure 4). The
colocalization of IgA antibody staining with the
monoclonal anti-a1(IV) antibody, as well as the West-
ern blotting with ﬁbroblast collagen IV, and the
pattern of IgA deposition along the GBM, Bowman’s
capsule, mesangial matrix, and tubular basement
membranes localize the IgA antibody epitope to the
collagenous domain of a1(IV).
The occurrence of IgA anti-GBM disease in very
uncommon. Among 53 patients who presented with
anti-GBM disease in 2 local renal units over the past 3ere centrifuged using a Cytospin centrifuge on Superfrost slides
nd incubated with (a) mouse antihuman a1(IV) monoclonal antibody
visualized with Alexa 488 and (b) acute and (d) patient convalescent
ted overnight at 4 C and visualized with Alexa Fluor 647labeled
rged image of (a) and (b) demonstrating colocalization of IgA anti-
165
Table 1. Teaching points
 Conventional antiglomerular basement membrane (anti-GBM) assays used in clinical
practice would not detect IgA antibodies or those directed against other target antigens
such a5(IV) found in some Alport disease patients following renal transplantation.
 Delayed establishment of the correct diagnosis and treatment of anti-GBM disease can
result in need for permanent renal replacement therapy.
 If the clinical presentation and histopathological ﬁndings are suggestive of anti-GMB
disease in the absence of positive serology results, alternative laboratory tests such as
immunoblotting and indirect immunoﬂuorescence can be used to conﬁrm the
diagnosis.
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disease that we have encountered. So far, only 13
cases have been reported in the literature.3–16 In all
cases, the histology was consistent with crescentic
glomerulonephritis and demonstrated linear GBM
staining with IgA. The percentage of crescentic
glomeruli ranged from 6% to 75%. Pulmonary hem-
orrhage was present in 6 of 12 cases (50%). At last
follow-up, 6 of 12 patients (50%) had died. Only 2
patients received a kidney transplant, in 1 of whom
there was recurrence of disease 2 years later in the
absence of a standard serological tests to monitor IgA
anti-GBM antibody titers.5,6,16 These outcomes
emphasize the importance of prompt diagnosis and
having the means to monitor the IgA anti-GBM
antibodies.
The speciﬁcity of the IgA anti-GBM antibodies has
been considered only twice. Similar to the epitope that
we identiﬁed, Borza et al. described the case of recur-
rent anti-GBM disease mediated by a monoclonal IgA
antibody that recognized epitopes located in the
collagenous domain of the a1/2(IV) collagen network.6
Interestingly, their patient’s IgA staining pattern also
demonstrated an additional prominent Bowman’s
capsule and mesangial staining, similar to our case. The
Bowman’s capsule, mesangial matrix, and tubular
basement membranes are rich in other a(IV) chains,
supporting the location of the IgA antibody epitope on
the a1/2(IV) chains.17 The second case was that of a
patient with crescentic glomerulonephritis and sub-
epidermal blisters, with IgA anti-GBM autoantibodies
directed against the noncollagenous domain of the a5
and a6 chains of type IV collagen.14
In 1988, Cederholm et al. were ﬁrst to describe
circulating IgAﬁbronectin complexes in IgA ne-
phropathy patients.18 The IgAﬁbronectin complexes
have an afﬁnity for the collagen backbone of all
collagen IV chains (a1–a6). To investigate an effect of
IgAﬁbronectin immune complexes mediating the
GBM binding, we performed western blot analysis
using the patient’s acute serum binding to ﬁbroblast-
derived collagen IV and developed with an anti-
ﬁbronectin secondary antibody. No binding was
found, suggesting that the antibody targeting the GBM166was not due to formation of IgAﬁbronectin com-
plexes (data not shown).
Interestingly, in 5 of 14 case reports, the patients had
concurrent autoimmune or alternative renal diseases:
Henoch–Schonlein purpura/IgA nephropathy,8,19
Crohn’s disease,9 systemic lupus erythematosus,13
autoimmune bullous dermatitis,14 and thin basement
membrane disease.12
Whether the coexistence of the conditions could
facilitate the development of anti-GBM disease is an
interesting hypothesis that remains to be proved.
Ongoing glomerular inﬂammation may alter GBM
components, triggering an autoimmune reaction to
modiﬁed antigens and subsequent production of
nephritogenic antibodies, as proposed for the associa-
tion between anti-GBM disease and ANCA
glomerulonephritis.20
Our patient received a cadaveric kidney transplant,
with no evidence of recurrence at 9-month follow-up.
In the past, recurrence of anti-GBM disease has
occurred in patients who underwent transplantation in
the presence of circulating anti-GBM antibodies. In the
absence of a validated IgA-GBM detection assay, our
modiﬁed indirect immunoﬂuorescence test demon-
strating a lack of IgA binding to the GBM with the
patient’s convalescent serum provided reassurance for
us to proceed with transplantation with minimal risk of
disease recurrence (Table 1).DISCLOSURE
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